Ibrutinib is a prescription-only Bruton's tyrosine kinase (BTK) inhibitor used for certain B-cell malignancies and chronic graft-versus-host disease.[1]
This directory includes 15 listed brands: 14 other products plus the originator Imbruvica. It is not a complete global list, and regulatory status may differ by product and country.[3]
Availability enquiries are handled by Medicine for World. Submission of an enquiry does not confirm regulatory eligibility, supply or delivery. Ownership and commercial disclosure
Ibrutinib is the international non-proprietary name of an oral Bruton's tyrosine kinase (BTK) inhibitor. Imbruvica was first approved in the United States in 2013 and received European Union marketing authorisation on 21 October 2014.[1][2]
According to the current US prescribing information (DailyMed, revised October 2025), Imbruvica is indicated for:[1]
Approved uses differ between countries. Whether ibrutinib is suitable, and at what dose, is decided by the treating oncologist. Warnings and side effects are listed in the official product information:
The products below are included for identification and availability-enquiry purposes. Inclusion does not mean that a product is authorised, approved, therapeutically equivalent or available in every country. Confirm regulatory status with the relevant national medicines authority.
Products are listed in alphabetical order. The list is not a ranking and makes no claim that one product is better than another.[3]
No product matches these filters.
Product listing data last checked October 4, 2026.
Imbruvica is the originator ibrutinib medicine. It is marketed by Pharmacyclics LLC / Janssen-Cilag and was the first ibrutinib product to be approved, by the US Food and Drug Administration in 2013. Other products represented as containing ibrutinib are made by other manufacturers and sold under their own brand names.[1][2]
The originator is shown here separately from the other listed products.
This comparison covers identity and listing information only. It does not establish regulatory approval, pharmaceutical equivalence, bioequivalence, quality, safety or clinical effectiveness.
| Attribute | Other listed ibrutinib products | Originator (Imbruvica) |
|---|---|---|
| Active substance | Ibrutinib, as listed. The salt form is not stated in the product listings.[3] | Ibrutinib[2] |
| Brand name | Each manufacturer's own brand name (14 products listed)[3] | Imbruvica[1] |
| Company | 13 different manufacturers, as listed[3] | Pharmacyclics LLC / Janssen-Cilag[1][2] |
| Dosage form | Capsule or tablet, as listed[3] | Capsule, film-coated tablet, or oral suspension (US label)[1] |
| Strengths | 140 mg for every listed catalogue product[3] | Capsules 70/140 mg; tablets 140/280/420 mg; suspension 70 mg/mL (US label)[1] |
| Regulatory approval | Varies by product and country. Not independently verified for this page; check with your national medicines authority. | US FDA approval 2013 · EU authorisation 2014[1][2] |
| Classification | Product represented by its manufacturer or supplier as containing ibrutinib. Regulatory classification must be confirmed in the relevant jurisdiction.[3] | Originator product[1][2] |
Tell us your country and the product information you are looking for.
Medicine for World reviews destination-country restrictions and may request prescription or treatment documentation through a secure channel.
If the request can lawfully be supported, you may receive current product information, availability and a quotation.
Any transaction is subject to prescription requirements, supplier checks, local law, import rules and final confirmation.
Submitting an enquiry does not guarantee availability, regulatory eligibility, import permission, delivery or a transaction.
Submit a non-binding enquiry. Medicine for World will review the destination country and available options before requesting any sensitive medical documents.
This service cannot assist with medical emergencies or treatment decisions. Contact your treating healthcare professional or local emergency service.
Ibrutinib is a prescription-only Bruton's tyrosine kinase (BTK) inhibitor. Current US prescribing information lists specific uses in CLL/SLL, Waldenström's macroglobulinemia and chronic graft-versus-host disease. The originator is Imbruvica.
14 products represented by their manufacturers or suppliers as containing ibrutinib: Brutini, Butinib, Emlutini, Ibrucent, Ibrucon, Ibrunib, Ibrutab, Ibrutech, Ibrutix / Ibrucon, Ibruxen, Ibutigen, ILUDX, LuciBru, and Notafol. It is not a complete global list, and inclusion does not mean a product is authorised or approved in any specific country.
Imbruvica, marketed by Pharmacyclics LLC / Janssen-Cilag. It was first approved in the United States in 2013 and authorised in the European Union in 2014.
All 15 catalogue records are listed at 140 mg; the catalogue includes capsules and tablets. The current US Imbruvica label also includes other strengths and an oral suspension.
This page does not establish regulatory approval, pharmaceutical equivalence, bioequivalence, quality, safety or clinical effectiveness for any listed product. Confirm regulatory status with the relevant national medicines authority.
This page does not rank or compare products and makes no claim about relative effectiveness or quality. The choice of medicine should be made with the treating doctor.
Submit a non-binding enquiry using the form on this page. Enquiries are handled by Medicine for World. Prices are not published; current information and a quotation are provided only if the request can lawfully be supported.
Initially only your name, country and one contact method. Medicine for World may later request prescription or treatment documentation through a secure channel. Do not send medical documents through this form.
MedFactHub is a commercial affiliate and referral website for Medicine for World. Availability enquiries are handled by Medicine for World, which may receive commercial benefit from a resulting transaction.
No. It gives information about medicine identity and listed products. Decisions about treatment, dose and duration belong to a qualified healthcare professional.
Current editorial and medical-review status is shown below. No independent medical review is claimed until it has been completed.
Medical and regulatory facts come from official product information. Product listing details come from a supplied dataset. Numbers in square brackets on this page refer to the sources below.